A US government advisor warned officials of the dangers of antibiotic-resistant anthrax while profiting from antitoxin sales.
Advertisement
The Scientist
Most Recent
Researchers responding to a survey at MD Anderson Cancer Center report low morale due to their president’s leadership style.
Biomedical groups propose a simplified system for the disclosure of potential conflicts of interests.
Charles Nemeroff, who was barred from receiving grants for 2 years in 2008, snags $401K from the NIH to study PTSD.
Simply disclosing conflicts of interest is not enough.
Some 85 percent of researchers involved in promoting off-label drug use do not adequately disclose financial conflicts of interest in published articles.
The American Association of University Professors releases recommendations for maintaining academic freedom while collaborating with industry.
Financial “conflicts of interest” should not be so quickly condemned. Industry relationships are unequivocally beneficial.
Major pharmaceutical companies have agreed to a handful of recommendations aimed at increasing the transparency of clinical trials they fund.
Editors at PLoS Medicine suggest that merely disclosing conflicts of interest is insufficient and possibly even counterproductive.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
